Erschienen in:
01.03.2021 | Movement Disorders (T. Simuni, Section Editor)
Huntington’s Disease: New Frontiers in Therapeutics
verfasst von:
Ling Pan, Andrew Feigin
Erschienen in:
Current Neurology and Neuroscience Reports
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
This article describes and discusses new potential disease-modifying therapies for Huntington’s disease that are currently in human clinical trials as well as promising new therapies in preclinical development.
Recent Findings
Multiple potential disease-modifying therapeutics for HD are in active development, including direct DNA/gene therapies, RNA modulation, and therapies targeted at aberrant downstream pathways.
Summary
The etiology of Huntington’s disease (HD) is well-known as an abnormally expanded trinucleotide repeat within the huntingtin gene. However, the pathogenesis downstream of the mutant huntingtin gene is complex, involving multiple toxic pathways, including abnormal protein fragmentation and neuroinflammation. The current treatment of HD focuses largely on symptomatic management. This article discusses new, potential disease-modifying therapies that are currently in human clinical trials and preclinical development.